Skip to main content
TipRanks
Go Ultimate75% OFF

Orthofix Medical (OM2) AI Stock Analysis

0 Followers
DE:OM2

Orthofix Medical

(Frankfurt:OM2)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue and margin improvementStrong revenue growth alongside higher EBITDA margins indicates improving operating leverage and better execution. Although profitability is not complete, the combination of scale and cost discipline can strengthen earnings capacity and provide a more durable foundation for future investment.
Negative Factors
Persistent cash burnDeeply negative free cash flow means the business is not currently self-funding despite improving revenue and EBITDA. Continued investment or working-capital needs may require external financing or constrain strategic flexibility until cash conversion improves consistently.

Orthofix Medical (OM2) vs. iShares MSCI Germany ETF (EWG)

-60%-50%-40%-30%-20%-10%0%10%20%DE:OM2-51.24%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 269.42M
Dividend Yield
―
Average Volume (3M)
25
Price to Earnings (P/E)
-5.9
Beta (1Y)
0.35
Revenue Growth
-2.99%
EPS Growth
66.06%
Country
Germany
Employees
1,605
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Orthofix Medical Business Overview & Revenue Model

Company Description

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Ge...

Orthofix Medical Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:-23.38%|Next Earnings Date:Feb 19, 2027
Earnings Call SentimentNeutral

The call presented a mixed outlook. Limb Reconstruction, Therapeutic Solutions, Biologics stabilization, technology launches and improved adjusted EBITDA were positive, but these were offset by below-expectation results, U.S. Spine weakness, supplier and instrument constraints, reduced 2026 guidance, unfavorable mix, cash timing pressure and a stated 2027 MDR revenue headwind.

Positive Updates

Quarterly Revenue Increased
Third quarter reported net sales were $207.9 million, an increase of 2.3% year-over-year. Growth in limb reconstruction and Therapeutic Solutions helped offset weaker Spine performance.

Negative Updates

Third-Quarter Results Were Below Expectations
Management stated that third-quarter results were below expectations, with U.S. Spine affected by market softness, unplanned supplier delays, inventory constraints and instrument set constraints.

Company Guidance

Orthofix now expects full year 2026 pro forma net sales in the range of $825 million to $830 million and full year 2026 non-GAAP adjusted EBITDA of $86 million to $88 million, with the outlook provided on a non-GAAP pro forma basis, reflecting current foreign currency exchange rates and excluding the discontinued M6 product lines. For the fourth quarter, the company expects sequential growth from normal seasonality and inventory purchases under the European distributor arrangement, with most of the approximately $15 million 2026 net sales benefit expected in the fourth quarter. The European MDR strategy for Spine is expected to create an approximately $22 million net sales headwind in 2027, while MDR requirements are completed. The company is not providing full guidance on 2027, but expects Therapeutic Solutions and limb recon to show above-market growth, core revenue to be in the positive territory backing out the MDR, and Q3, Q4 performance to continue into 2027; core distributors’ growth slowed to the mid-single digits.

Orthofix Medical Risk Analysis

Orthofix Medical disclosed 54 risk factors in its most recent earnings report. Orthofix Medical reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk
1.The U.S. Food and Drug Administration's ("FDA") reclassification of bone growth stimulator devices from Class III to Class II may increase competition and adversely affect our future sales.Q3, 2026

Orthofix Medical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:OM2 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GMEDGMED73Outperform$9.27B17.0411.82%―13.35%32.22%
SIBNSIBN70Outperform$1.04B-75.98-7.57%―13.99%39.54%
BVSBVS66Neutral$894.85M12.5527.23%―3.87%623.68%
ENOVENOV58Neutral$1.56B-2.92-35.53%―3.28%62.02%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ATECATEC50Neutral$1.10B-12.61-547.17%―15.34%46.31%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:OM2ATECENOVGMEDSIBNBVSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:OM2 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:OM2Orthofix Medical Inc.5.90-6.40-52.03%
ATECAlphatec7.06-12.55-64.00%
ENOVEnovis Corporation27.100.271.01%
GMEDGlobus Medical70.53-11.75-14.28%
SIBNSi-Bone23.544.8626.02%
BVSBioventus, Inc.10.624.0962.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.